Related Experiment Videos
PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far?
P J Vlachostergios1, A M Molina1
1Division of Hematology and Medical Oncology, Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, USA.
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Smart Release Nano-formulation of Cytochrome C and Hyaluronic Acid Induces Apoptosis in Cancer Cells.
Journal of nanomedicine & nanotechnology·2017
Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy.
Critical reviews in oncology/hematology·2015
Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
Annals of oncology : official journal of the European Society for Medical Oncology·2014
Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials.
European journal of cancer (Oxford, England : 1990)·2013
Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2013
Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 Trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti-PD-(L)1 therapy.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020).
Annals of oncology : official journal of the European Society for Medical Oncology·2026
A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: Results of the international IROCAS study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026